ライフサイエンスコーパス: nonmuscle

1 a preference for actin isoforms, nucleating nonmuscle actin but not muscle actin, which has not been

2 t prolyl hydroxylase 3 (PHD3) interacts with nonmuscle actin in human cells and catalyzes hydroxylati

3 ver, it was only 40 years ago that the first nonmuscle actin-binding protein, filamin, was identified

4 Subsequently many other nonmuscle actin-binding proteins were identified and cha

5 beta- and gamma-nonmuscle actins differ by 4 amino acids at or near the

6 ty through posttranslational modification of nonmuscle actins.

7 filament disassembly but not with UNC-60A, a nonmuscle ADF/cofilin.

8 us CHC22 and CHC17 function independently in nonmuscle and muscle cells.

9 Contractility of the nonmuscle and smooth muscle cells that comprise biologic

10 ted from the original MYLK gene that encodes nonmuscle and smooth muscle myosin light chain kinase (s

11 me courses of human cofilin binding to human nonmuscle (beta-, gamma-) actin filaments.

12 Here we show that nonmuscle CaD is highly expressed in both premigratory a

13 his similarity explains the fact that single nonmuscle cell and whole-muscle contraction both follow

14 ation and derepression of genes expressed in nonmuscle cell lineages.

15 actin phosphorylation has been implicated in nonmuscle cell migration.

16 adapter protein that has been implicated in nonmuscle cell migration.

17 and in turn, promote better understanding of nonmuscle cell motility.

18 that could be responsible for the variety of nonmuscle cell movements, including the "saltatory cytop

19 critical for numerous aspects of muscle and nonmuscle cell physiology.

20 induced pluripotent stem cells), and various nonmuscle cell types all show that actomyosin-driven nuc

21 he potential transcriptional diversity among nonmuscle cell types within dystrophic muscle has not be

22 rangements that bring about contractility in nonmuscle cells are currently debated.

23 in humans and may reduce oxidative stress in nonmuscle cells in vitro.

24 to calcium regulation, but its regulation in nonmuscle cells is not understood.

25 sin-based contractility in smooth muscle and nonmuscle cells is regulated by signaling through the sm

26 thermore, we show that induction of Myod1 in nonmuscle cells is sufficient to redirect Smad3 to Myod1

27 One wondered whether nonmuscle cells might have a myosin-like molecule, well

28 udy indicated that myomaker could be used in nonmuscle cells to induce fusion with muscle in vivo, th

29 udy indicated that myomaker could be used in nonmuscle cells to induce fusion with muscle in vivo, th

30 in that enables muscle cells to contract and nonmuscle cells to move and change shape(1).

31 -powered force generation and contraction in nonmuscle cells underlies many cell biological processes

32 n kinase family associated with apoptosis in nonmuscle cells where it phosphorylates myosin regulator

33 gy-conserving storage molecule in muscle and nonmuscle cells(9-12), which can be activated to form fu

34 in filaments can assemble and disassemble in nonmuscle cells, and in some smooth muscle cells, but wh

35 ut mice to investigate the role of Myo18A in nonmuscle cells, exemplified by macrophages, which expre

36 Previous work, in nonmuscle cells, has shown that Hsp27 inhibits TNF-alpha

37 filaments drive many essential processes in nonmuscle cells, including migration and adhesion.

38 In eukaryotic nonmuscle cells, regulation of the homodimeric actin cro

39 tin bundlers that are inhibited by Ca(2+) in nonmuscle cells.

40 he structure and motility of both muscle and nonmuscle cells.

41 to generate contractile forces in muscle and nonmuscle cells.

42 ovement observed in actomyosin assemblies in nonmuscle cells.

43 dered actomyosin bundles found in muscle and nonmuscle cells.

44 e actomyosin assemblies in smooth muscle and nonmuscle cells.

45 and cellular and intracellular movements in nonmuscle cells.

46 stability of actin in eukaryotic muscle and nonmuscle cells.

47 yosin contraction found in smooth muscle and nonmuscle cells.

48 ved network architecture that also exists in nonmuscle cells.

49 translocation, a phenomenon also observed in nonmuscle cells.

50 oblasts differentiating into myotubes and in nonmuscle cells.

51 mical energy into force/motion in muscle and nonmuscle cells.

52 ontraction and have key roles in motility of nonmuscle cells.

53 hesion, morphogenesis, and mechanosensing in nonmuscle cells.

54 ports a vast number of cellular processes in nonmuscle cells.

55 Nonmuscle cortical actomyosin networks are thought to co

56 ishing bladder cancer from controls and also nonmuscle from muscle-invasive bladder cancer.

57 quires proper assembly and regulation of the nonmuscle gamma isoactin-rich cytoskeleton, and six poin

58 Currently, ten point mutations in nonmuscle gamma-actin have been identified as causing pr

59 ngle- and double-headed myosin fragments and nonmuscle IIB thick filaments.

60 rains are considered in muscle fibers and in nonmuscle intracellular cargo transport.

61 as follows: LGN = low grade (grade 1 or 2), nonmuscle invading (stage Ta or T1); HGN = high grade (g

62 = high grade (grade 3 or carcinoma in situ), nonmuscle invading (stage Ta, T1, or TIS); and INV = any

63 ve higher mortality rates than patients with nonmuscle invasive ('superficial') bladder cancer.

64 optimal treatment of patients with high-risk nonmuscle invasive (HGT1) micropapillary variant of blad

65 is challenging, especially in the setting of nonmuscle invasive (NMI) disease.

66 High-risk, nonmuscle invasive bladder cancer (HR-NMIBC) represents

67 High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterog

68 /25 (92.0%) patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after inductio

69 Once diagnosed, patients with nonmuscle invasive bladder cancer (NMIBC) are committed

70 PURPOSE OF REVIEW: As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high pro

71 The management of nonmuscle invasive bladder cancer (NMIBC) recurrent afte

72 ravesical bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer (NMIBC).

73 roversies in the diagnosis and management of nonmuscle invasive bladder cancer (NMIBC).

74 DINGS: The mainstay definitions of high-risk nonmuscle invasive bladder cancer are based on grade and

75 PURPOSE OF REVIEW: Nonmuscle invasive bladder cancer represents a large maj

76 The management of nonmuscle invasive bladder cancer with variant histology

77 ts should change management of patients with nonmuscle invasive bladder cancer.

78 of microRNAs to help evaluate patients with nonmuscle invasive bladder cancer.

79 Management of high-risk patients with nonmuscle invasive cancer continues to be controversial,

80 In patients with nonmuscle invasive cancer, there is a need for enhanced

81 r, with a focus upon their role in high-risk nonmuscle invasive tumors.

82 setting of an acute or chronic cystitis and nonmuscle invasive-type CIS.

83 thelial carcinomas, both muscle invasive and nonmuscle invasive.

84 tiveness and harms of interventions for both nonmuscle-invasive and muscle-invasive disease will enha

85 and controversies in the management of both nonmuscle-invasive and muscle-invasive urothelial carcin

86 treatment for muscle-invasive and high-risk nonmuscle-invasive bladder cancer (BCa), but is associat

87 Trials in nonmuscle-invasive bladder cancer are evaluating the rol

88 improvements in diagnosis and management of nonmuscle-invasive bladder tumors, the risk of both recu

89 Management of high-risk patients with nonmuscle-invasive cancer remains a challenge, with cont

90 tion to risk stratification of patients with nonmuscle-invasive tumors permits appropriate timing of

91 prevalent in muscle-invasive UCB compared to nonmuscle-invasive UCB.

92 sin genes imply the existence of additional, nonmuscle isoforms.

93 Both ERK1/2 activity and nonmuscle l-caldesmon phosphorylation are blocked by h3/

94 y PRC1/Bmi1 concentrates at genes specifying nonmuscle lineages, helping to retain H3K27me3 in the fa

95 tion focuses on the possibility of targeting nonmuscle members of the human myosin family for several

96 n-cell-autonomously, acting through adjacent nonmuscle mesenchyme.

97 e more abundant and persistently unpolarized nonmuscle MIIA (myosin-IIA).

98 We show that nonmuscle MIIB (myosin-IIB) is unpolarized in cells on s

99 The motor protein myosin drives muscle and nonmuscle motility by binding to and moving along actin

100 The 3 isoforms of nonmuscle myosin (NM) II (NMII-A, NMII-B, and NMII-C) pl

101 Ablation of nonmuscle myosin (NM) II-A or NM II-B results in mouse e

102 y cancers are known to show up-regulation of nonmuscle myosin (NM) IIA and IIB, the mechanism by whic

103 alization of two motor complexes, dynein and nonmuscle myosin (NM)II.

104 e the behavior of the cortical motor protein nonmuscle myosin (NMY-2) to complement recent efforts th

105 Inhibition and ablation of nonmuscle myosin 2 (NM2) paralogues have demonstrated th

106 We discovered that nonmuscle myosin 2A (NM2A) directly bound the BAR-PH tan

107 Inhibitors of nonmuscle myosin activity repressed the assembly of myof

108 gulator of this process as it activates both nonmuscle myosin and a nucleator of actin filaments [1].

109 mask-plating, or inhibition of Rho kinase or nonmuscle myosin attenuated stress fiber accumulation an

110 Nonmuscle myosin copurifies with polysomes, and there is

111 Here we show that intact nonmuscle myosin filaments are required for the synthesi

112 cate that association of collagen mRNAs with nonmuscle myosin filaments is necessary to coordinately

113 Dissociation of nonmuscle myosin filaments results in secretion of colla

114 in vitro by studying mice and cells in which nonmuscle myosin heavy chain (NMHC) II-A is genetically

115 e studied 2 transgenic mouse models in which nonmuscle myosin heavy chain (NMHC) II-A was genetically

116 ternative splicing of a cassette exon N30 of nonmuscle myosin heavy chain (NMHC) II-B in the mouse ce

117 ium (LD) detected strong association between nonmuscle myosin heavy chain 9 gene (MYH9) variants on c

118 monoclonal antibody (m21G6) directed against nonmuscle myosin heavy chain II may inhibit IgM binding

119 A highly conserved self-antigen, nonmuscle myosin heavy chain II, has been identified as

120 Subset 6 CLL mAbs recognize nonmuscle myosin heavy chain IIA (MYHIIA).

121 c variants of the MYH9 gene that encodes the nonmuscle myosin heavy chain IIA are associated with dia

122 otein S100A4 and the C-terminal fragments of nonmuscle myosin heavy chain IIA has been studied by equ

123 we have also identified a new Rab3 effector, nonmuscle myosin heavy chain IIA, as part of the complex

124 we reported that RUNX1-mediated silencing of nonmuscle myosin heavy chain IIB (MYH10) was required fo

125 Proteomic screening identified nonmuscle myosin heavy chain IIB (NMHCIIB), a subunit of

126 , localization of the actin-bundling protein nonmuscle myosin heavy chain IIB, and junction remodelin

127 desmoplakin, fibrillarin, nuclear lamin B1, nonmuscle myosin heavy chain IIB, paxillin, Sec61 beta,

128 en the Wingless (Wg) signaling pathway and a nonmuscle myosin heavy chain, encoded by the crinkled (c

129 Nonmuscle myosin II (MII) is a critical mediator of cont

130 omprising actin, cross-linking proteins, and nonmuscle myosin II (MII), begins to reassemble on the m

131 Nonmuscle myosin II (Myo-II) activity at the cluster per

132 Activation of nonmuscle myosin II (Myo-II) by kinases such as Rho-asso

133 myosin networks are thought to contract when nonmuscle myosin II (myosin) is activated throughout a m

134 Here, we demonstrate that nonmuscle myosin II (NM II) is required for the internal

135 Nonmuscle myosin II (NM II) powers myriad developmental

136 t contractile ring constriction is driven by nonmuscle myosin II (NM II) translocation of antiparalle

137 Bleb formation has been correlated with nonmuscle myosin II (NM-II) activity.

138 Nonmuscle myosin II (NM-II) is an important motor protei

139 However, the mechanisms by which nonmuscle myosin II (NM-II) is recruited to those struct

140 merization or by inhibiting the actin driver nonmuscle myosin II (NMII) in the BLA or systemically.

141 Nonmuscle myosin II (NMII) is thought to be the master i

142 Nonmuscle myosin II (NMII) is uniquely responsible for c

143 cological inhibition or genetic silencing of nonmuscle myosin II (NMII) markedly accelerates axon gro

144 These cell shape changes are controlled by nonmuscle myosin II (NMII) motor proteins, which are tig

145 The motor protein nonmuscle myosin II (NMII) must undergo dynamic oligomer

146 Nonmuscle myosin II (NMII) plays central roles during ce

147 ber and increased fibripositor length; thus, nonmuscle myosin II (NMII) powers the transport of these

148 A nonmuscle myosin II (NMII) reporter revealed pulsatile c

149 To identify novel regulators of nonmuscle myosin II (NMII) we performed an image-based R

150 In this study, we show that the role of nonmuscle myosin II (NMII)-B in front-back migratory cel

151 ifferentially interacts with the isoforms of nonmuscle myosin II (NMIIA, K(d) = 0.5 muM; IIB, K(d) =

152 CTN4 formed unbroken continuous rings, while nonmuscle myosin II (NMMII) formed linear tracts along t

153 erator in contractile actomyosin networks is nonmuscle myosin II (NMMII), a molecular motor that asse

154 nd contractile forces generated within it by nonmuscle myosin II (NMY-2) drive cellular morphogenetic

155 cts of TNF-alpha signaling, including apical nonmuscle myosin II accumulation and myosin light chain

156 We identified that increased nonmuscle myosin II activation and cellular contraction

157 Inhibition of nonmuscle myosin II activation may provide a novel appro

158 We demonstrate that nonmuscle myosin II activity guides adhesion phenotype i

159 ; however, there was no detectable change in nonmuscle myosin II activity in nesprin-1 deficient cell

160 tension induced by perturbations that alter nonmuscle myosin II activity.

161 A activity and associated Rho kinase-induced nonmuscle myosin II activity.

162 creases in retrograde actin network flow and nonmuscle myosin II activity.

163 end genetic interaction studies to show that nonmuscle myosin II and an unconventional myosin, encode

164 Subsequently, bridge bundles recruit nonmuscle myosin II and mature into stress fibers.

165 Additional requirements for nonmuscle myosin II are in the correct formation of othe

166 associated with an accumulation of actin and nonmuscle myosin II around the wound, forming a purse st

167 These MTs suppress Rho activation, nonmuscle myosin II bipolar filament assembly, and actin

168 In vivo, thorough depletion of nonmuscle myosin II delayed furrow initiation, slowed F-

169 Inhibition of nonmuscle myosin II dissipates this traction polarizatio

170 the elucidation of post-embryonic roles for nonmuscle myosin II during targeted stages of fly develo

171 onstrate that truncation alleles can perturb nonmuscle myosin II function via two distinct mechanisms

172 tional perturbation, in a graded fashion, of nonmuscle myosin II function.

173 While nonmuscle myosin II has been studied extensively in the

174 Mice carrying floxed alleles of the nonmuscle myosin II heavy chain gene (NMHC IIA(flox/flox

175 Despite functional significance of nonmuscle myosin II in cell migration and invasion, its

176 nced by increased RhoA activity, anillin and nonmuscle myosin II in the cytokinetic ring, and faster

177 Nonmuscle myosin II inhibition (NMIIi) in the basolatera

178 ly reduced translocation velocity, while the nonmuscle myosin II inhibitor blebbistatin and the kines

179 he mammalian homologue of Lgl (Lgl1) and the nonmuscle myosin II isoform A (NMII-A).

180 Although immature megakaryocytes express 2 nonmuscle myosin II isoforms (MYH9 [NMIIA] and MYH10 [NM

181 in II rather than the ubiquitously expressed nonmuscle myosin II isoforms, suggesting that a rich fun

182 has a distinct myosin population containing nonmuscle myosin II isoforms, which is regulated by phos

183 blocked by inhibiting RLC phosphorylation or nonmuscle myosin II motor activity.

184 The nonmuscle myosin II motor protein produces forces that a

185 ch in turns promotes the accumulation of the nonmuscle myosin II NMY-2 and the midbody component CYK-

186 The nonmuscle myosin II NMY-2 is required for cytokinesis as

187 s provided by the recruitment of F-actin and nonmuscle myosin II on the granule membranes that is tri

188 sion, suggesting that they are selective for nonmuscle myosin II over skeletal myosin.

189 Nonmuscle myosin II plays essential roles in embryonic d

190 Microtubule-directed nonmuscle myosin II polarization is aberrant in embryos

191 Nonmuscle myosin II produces contractile forces involved

192 l activation, we observed phosphorylation of nonmuscle myosin II regulatory light chain (RLC), which

193 rrow regression, but also mislocalization of nonmuscle myosin II with a phosphorylated myosin regulat

194 Interestingly, blocking activity of NMII (nonmuscle myosin II) either before, or after, lumen morp

195 gs were caused by Rac-mediated inhibition of nonmuscle myosin II, a cell polarity determinant.

196 development they demonstrate novel roles for nonmuscle myosin II, including in adhesion between the d

197 We show that two isoforms of nonmuscle myosin II, NMIIA and NMIIB, control distinct s

198 d mechanistic impact of platelets, including nonmuscle myosin II, red blood cells (RBCs), fibrin(ogen

199 CAFs align the Fn matrix by increasing nonmuscle myosin II- and platelet-derived growth factor

200 To investigate the contribution of nonmuscle myosin II-A (NM II-A) to early cardiac develop

201 lines, each with a different mutation in the nonmuscle myosin II-A gene, Myh9 (R702C, D1424N, and E18

202 Overall, 4-HAP modifies nonmuscle myosin II-based cell mechanics across phylogen

203 Pharmacologic inhibition of nonmuscle myosin II-based contractility blunts this rigi

204 The functional role of the C2 insert of nonmuscle myosin II-C (NM II-C) is poorly understood.

205 We have reported previously that nonmuscle myosin II-interacting guanine nucleotide excha

206 zing formins; and with zipper, which encodes nonmuscle myosin II.

207 he other, driven by oscillations of cortical nonmuscle myosin II.

208 signaling pathway, including Rho GTPase and nonmuscle myosin II.

209 eletal protein actin and the molecular motor nonmuscle myosin II.

210 a cortical ring rich in actin filaments and nonmuscle myosin II.

211 response to mechanical stress, specifically nonmuscle myosin IIA (MYH9) and IIC (MYH14), alpha-actin

212 Nonmuscle myosin IIA (NMIIA) heavy chain gene (MYH9) mut

213 In studies initially focused on roles of nonmuscle myosin IIA (NMIIA) in the developing mouse epi

214 also depends on the contractile activity of nonmuscle myosin IIA (NMIIA) motor proteins.

215 It binds to the nonmuscle myosin IIA (NMIIA) tail near the assembly comp

216 In addition, MyoGEF co-localizes with nonmuscle myosin IIA (NMIIA) to the front of migrating c

217 -interacting protein, cofilin, Munc13-4, and nonmuscle myosin IIA (NMIIA).

218 (2+)]i, and the association of gelsolin with nonmuscle myosin IIA (NMMIIA) at collagen adhesions are

219 recipitates showed that FliI associated with nonmuscle myosin IIA (NMMIIA), which was confirmed by im

220 induced actin polymerization, down-regulates nonmuscle myosin IIA activity, and destabilizes kidney p

221 1B, a component of the Sec61 translocon, and nonmuscle myosin IIA and beta-actin.

222 reviously that NK-cell cytotoxicity requires nonmuscle myosin IIA function and that granule-associate

223 The nonmuscle myosin IIA heavy chain (Myh9) is strongly asso

224 trongly suggest that base-line expression of nonmuscle myosin IIA inhibits osteoclast precursor fusio

225 We also found that nonmuscle myosin IIA is a major determinant of ROCK1 cor

226 tal muscle myosin, nonmuscle myosin IIB, and nonmuscle myosin IIA revealed three distinct regimes of

227 on epithelial cadherin (E-cadherin), NMMIIA (nonmuscle myosin IIA), and p120-catenin.

228 CMIIB), Dictyostelium myosin II (DdMII), and nonmuscle myosin IIA, as well as myosin V.

229 by Mg(2+) in myosin V, smooth muscle myosin, nonmuscle myosin IIA, CMIIB, and DdMII, although the ADP

230 omplex transported to the plasma membrane by nonmuscle myosin IIA-dependent trafficking in human lung

231 f our top hits-including Myh9, which encodes nonmuscle myosin IIa-have not been linked to tumor devel

232 icity of tractions depend on the activity of nonmuscle myosin IIA.

233 in cell culture, including tumor suppressor nonmuscle myosin IIA.

234 is dependent on actin and the involvement of nonmuscle myosin IIA.

235 tropomyosin 4.2 (TPM4), vinculin (VCL), and nonmuscle myosin IIB (NM-2B, MYH10).

236 Nonmuscle myosin IIB (NMIIB) is a cytoplasmic myosin, wh

237 he discovery of a viable therapeutic target, nonmuscle myosin IIB (NMIIB), a molecular motor that sup

238 osin heavy chain IIB (NMHCIIB), a subunit of nonmuscle myosin IIB (NMIIB), as an ER stress-dependent

239 Suppressing nonmuscle myosin IIB disrupts directional cell rearrange

240 al. report that a short serine-rich motif in nonmuscle myosin IIB is required to establish the cell's

241 s and show that the individual nonprocessive nonmuscle myosin IIB molecules form a highly processive

242 rs representative of skeletal muscle myosin, nonmuscle myosin IIB, and nonmuscle myosin IIA revealed

243 This zone is also enriched for nonmuscle myosin IIB.

244 leus, enriched in tropomodulin 1 (Tmod1) and nonmuscle myosin IIB.

245 ngly to a homologous heavy chain fragment of nonmuscle myosin IIC as to NMIIA.

246 Nonmuscle myosin IIs (NM IIs) are a group of molecular m

247 of solutions of polymerized unphosphorylated nonmuscle myosin IIs (NM2s), and this is reversed by pho

248 studies has revealed the distinct roles of 2 nonmuscle myosin IIs (NMIIs) on MK endomitosis: only NMI

249 Concurrent, but not individual, knockdown of nonmuscle myosin isoforms IIA and IIB also decreases con

250 The mylk1 gene encodes a 220-kDa nonmuscle myosin light chain kinase (MLCK), a 130-kDa sm

251 ry mediated by TRPC6, in turn, activates the nonmuscle myosin light chain kinase (MYLK), which not on

252 Nonmuscle myosin light chain kinase (nmMLCK), a multi-fu

253 Nonmuscle myosin light-chain kinase (nmMLCK), the predom

254 Boyden chambers, we demonstrated the role of nonmuscle myosin light-chain kinase (nmMYLK) in Tat(1)(-

255 Nonmuscle myosin light-chain kinase contributes to ather

256 We found that polarized distributions of the nonmuscle myosin NMY-2 at the cell cortex are independen

257 osphorylated Sqh, the Drosophila ortholog of nonmuscle myosin regulatory light chain (MRLC), which wa

258 MLC-4, a nonmuscle myosin regulatory light chain, localizes to sm

259 LARP6 interacts with nonmuscle myosin through its C-terminal domain and assoc

260 Here, we show that nonmuscle myosin type IIA (NM-IIA) interacts with MG53 t

261 response mediated by natural IgM directed to nonmuscle myosin with complement activation that results

262 ates activity of RhoA and phosphorylation of nonmuscle myosin, both implicated in actomyosin contract

263 ynaptic strength was distinct from that of a nonmuscle myosin, myosin IIb.

264 onsensus amino acid Met466 in the Drosophila nonmuscle myosin-2 active-site loop switch-2 acts as ble

265 the overall enzymatic signatures across the nonmuscle myosin-2 complement from model organisms indic

266 Together, these data show that Drosophila nonmuscle myosin-2 is a bona fide molecular motor and es

267 Nonmuscle myosin-2 is the primary enzyme complex powerin

268 Drosophila nonmuscle myosin-2 is uniquely insensitive toward blebbi

269 e kinetic characterization of the Drosophila nonmuscle myosin-2 motor domain.

270 x, the relay helix, and the lever, abolishes nonmuscle myosin-2 specific kinetic signatures.

271 complexes containing filamentous beta-actin, nonmuscle myosin-2B (NM-2B) constructs, and either tropo

272 Treatment with 4-HAP activates nonmuscle myosin-2C (NM2C) (MYH14) to alter actin organi

273 Here we identify nonmuscle myosin-2C (NM2C) as a component of the termina

274 tate (ADPVO4) crystal structure of the human nonmuscle myosin-2C motor domain, one of the slowest myo

275 icates that the Drosophila protein resembles nonmuscle myosin-2s from metazoa rather than protozoa, t

276 inesis, consistent with their known roles in nonmuscle myosin-dependent cytokinesis.

277 es that in other cell types are modulated by nonmuscle myosin-II (MII) forces and matrix mechanics.

278 odel for collective cell migration, requires nonmuscle myosin-II (Myo-II).

279 y pharmacologic inhibition of myosin-II, but nonmuscle myosin-IIA (MIIA) mutations paradoxically caus

280 olymerization and is negatively regulated by nonmuscle myosin.

281 ation and is negatively regulated by Rho and nonmuscle myosin.

282 Mammalian cells express three Class II nonmuscle myosins (NM): NM2A, NM2B, and NM2C.

283 most closely related to conventional class-2 nonmuscle myosins (NM2).

284 Nonmuscle myosins (NMs) II-A and II-B are essential for

285 In contrast to nonmuscle myosins from animal cells that require phospho

286 ases, the activity of motor proteins such as nonmuscle myosins is required for appropriate constricti

287 ultured human cholangiocytes express several nonmuscle myosins, including myosins IIA and IIB.

288 not identical energetics in both muscle and nonmuscle myosins.

289 nal in vivo and whether the newly introduced nonmuscle nuclei undergoes nuclear reprogramming has not

290 al activity of different types of muscle and nonmuscle nuclei.

291 lue 2-fold greater than the value for smooth/nonmuscle RLC; cardiac RLC is a favorable biochemical su

292 cytokine action on muscle promotes atrophy, nonmuscle sites of action for inflammatory mediators are

293 y mixtures of F-actin and thick filaments of nonmuscle, smooth, and skeletal muscle myosin isoforms w

294 preparation to isolate forces contributed by nonmuscle structures within the tail.

295 ature of cardiac, skeletal muscle, and other nonmuscle systems requires further analysis to take into

296 The actin-binding protein nonmuscle tropomyosin (Tm) provides spatially specific r

297 Only one nonmuscle tropomyosin (Tm1A) has previously been describ

298 ntifies and characterizes previously unknown nonmuscle tropomyosins in Drosophila, 2) reveals a funct

299 orylation may be a key mode of regulation of nonmuscle tropomyosins, which in fission yeast controls

300 , indicating that dysferlin is important for nonmuscle vesicular trafficking.